{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:11:32Z","timestamp":1793398292191,"version":"4.5.0"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:p>Glaucoma is a major cause of irreversible blindness worldwide. Reducing intraocular pressure (IOP) is currently the only approach to prevent further optic nerve head damage. Pharmacotherapy is the mainstay of treatment for glaucoma patients. In recent years, a significant milestone in glaucoma treatment has been a transition to prostaglandin analogs (PGAs) as the first line of drugs. The rapid shift from traditional \u03b2-blockers to PGAs is primarily due to their excellent efficacy, convenient once-a-day usage, better diurnal control of IOP, and systemic safety profiles. This review article aims to provide information regarding the various PGAs in practice and also the newer promising drugs.<\/jats:p>","DOI":"10.4103\/ijo.ijo_2706_22","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T03:29:22Z","timestamp":1684294162000},"page":"1768-1776","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":30,"title":["Prostaglandin analogs in ophthalmology"],"prefix":"10.4103","volume":"71","author":[{"given":"S","family":"Subbulakshmi","sequence":"first","affiliation":[{"name":"Department of Glaucoma, Aravind Eye Hospital, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasan","family":"Kavitha","sequence":"additional","affiliation":[{"name":"Department of Glaucoma, Aravind Eye Hospital, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rengaraj","family":"Venkatesh","sequence":"additional","affiliation":[{"name":"Department of Glaucoma, Aravind Eye Hospital, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"R1-20251006","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040:A systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"key":"R2-20251006","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/14740338.2022.1996560","article-title":"A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension","volume":"21","author":"Katsanos","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"R3-20251006","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","article-title":"Comparative effectiveness of first-line medications for primary open-angle glaucoma:A systematic review and network meta-analysis","volume":"123","author":"Li","year":"2016","journal-title":"Ophthalmology"},{"key":"R4-20251006","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1177\/1060028014548569","article-title":"Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension","volume":"48","author":"Lin","year":"2014","journal-title":"Ann Pharmacother"},{"key":"R7-20251006","doi-asserted-by":"crossref","first-page":"P71","DOI":"10.1016\/j.ophtha.2020.10.022","article-title":"Primary open-angle glaucoma preferred practice pattern\u00ae","volume":"128","author":"Gedde","year":"2021","journal-title":"Ophthalmology"},{"key":"R8-20251006","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1113\/jphysiol.1966.sp007812","article-title":"Some differences in uveal reactions between cats and rabbits","volume":"182","author":"Ambache","year":"1966","journal-title":"J Physiol"},{"key":"R9-20251006","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF02173538","article-title":"The effects of prostaglandin F2 alpha in the human eye","volume":"222","author":"Giuffr\u00e8","year":"1985","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R10-20251006","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2165\/00002512-199914050-00006","article-title":"Prostaglandin analogues in the treatment of glaucoma","volume":"14","author":"Lind\u00e9n","year":"1999","journal-title":"Drugs Aging"},{"key":"R11-20251006","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/13543776.2019.1661992","article-title":"Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013-2018)","volume":"29","author":"Angeli","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"R12-20251006","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/jop.2013.0179","article-title":"Effects of prostaglandin analogues on aqueous humor outflow pathways","volume":"30","author":"Winkler","year":"2014","journal-title":"J Ocul Pharmacol Ther"},{"key":"R13-20251006","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/108076803322660422","article-title":"Ocular hypotensive FP prostaglandin (PG) analogs:PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells","volume":"19","author":"Sharif","year":"2003","journal-title":"J Ocul Pharmacol Ther"},{"key":"R14-20251006","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0014-4835(89)90011-0","article-title":"Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey","volume":"48","author":"Nilsson","year":"1989","journal-title":"Exp Eye Res"},{"key":"R15-20251006","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1167\/iovs.13-12363","article-title":"Differential effects of prostaglandin E2-sensitive receptors on contractility of human ocular cells that regulate conventional outflow","volume":"54","author":"Wang","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R16-20251006","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","article-title":"Intraocular pressure-lowering effects of all commonly used glaucoma drugs:A meta-analysis of randomized clinical trials","volume":"112","author":"van der Valk","year":"2005","journal-title":"Ophthalmology"},{"key":"R17-20251006","doi-asserted-by":"crossref","first-page":"3190684","DOI":"10.1155\/2018\/3190684","article-title":"Washout duration of prostaglandin analogues:A systematic review and meta-analysis","volume":"2018","author":"Diaconita","year":"2018","journal-title":"J Ophthalmol"},{"key":"R18-20251006","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0002-9394(98)00071-3","article-title":"Anterior uveitis associated with latanoprost","volume":"126","author":"Fechtner","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"R19-20251006","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ajo.2004.07.022","article-title":"Abdominal cramp as an adverse effect of travoprost","volume":"139","author":"Lee","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R20-20251006","first-page":"513","article-title":"Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogue","volume":"23","author":"Stjernschantz","year":"1995","journal-title":"Adv Prostaglandin Thromboxane Leukot Res"},{"issue":"(Suppl 1)","key":"R21-20251006","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0039-6257(02)00302-8","article-title":"Ocular and systemic pharmacokinetics of latanoprost in humans","volume":"47","author":"Sj\u00f6quist","year":"2002","journal-title":"Surv Ophthalmol"},{"key":"R22-20251006","first-page":"741","article-title":"Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension","volume":"4","author":"Lee","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"R23-20251006","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/bjo.85.8.983","article-title":"Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension","volume":"85","author":"Zhang","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"R24-20251006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/bjo.2007.123737","article-title":"The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine:A systematic review","volume":"92","author":"Hodge","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R25-20251006","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1097\/IJG.0000000000000158","article-title":"Meta-analysis of the efficacy and safety of latanoprost monotherapy in patients with angle-closure glaucoma","volume":"25","author":"Chen","year":"2016","journal-title":"J Glaucoma"},{"key":"R26-20251006","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/j.ophtha.2011.03.010","article-title":"Comparison of latanoprost and timolol in pediatric glaucoma:A phase 3, 12-week, randomized, double-masked multicenter study","volume":"118","author":"Maeda-Chubachi","year":"2011","journal-title":"Ophthalmology"},{"key":"R27-20251006","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/bjophthalmol-2012-302121","article-title":"Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma","volume":"97","author":"Rouland","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R28-20251006","first-page":"69","article-title":"Efficacy of latanoprost when stored at room temperature","volume":"57","author":"Mochizuki","year":"2008","journal-title":"Hiroshima J Med Sci"},{"key":"R29-20251006","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00061198-200110000-00010","article-title":"Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension","volume":"10","author":"Goldberg","year":"2001","journal-title":"J Glaucoma"},{"key":"R30-20251006","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0161-6420(02)01010-2","article-title":"Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure:A 6-month, masked, multicenter trial","volume":"109","author":"Fellman","year":"2002","journal-title":"Ophthalmology"},{"key":"R31-20251006","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaapos.2017.07.202","article-title":"A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension","volume":"21","author":"Dixon","year":"2017","journal-title":"J AAPOS"},{"key":"R32-20251006","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5301\/ejo.5000001","article-title":"Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma","volume":"22","author":"Gandolfi","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"R33-20251006","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1089\/jop.2021.0099","article-title":"Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost\/timolol fixed-dose combination therapy:Results from the VISIONARY study population in Spain","volume":"38","author":"Garcia-Medina","year":"2022","journal-title":"J Ocul Pharmacol Ther"},{"key":"R34-20251006","doi-asserted-by":"crossref","first-page":"474","DOI":"10.18240\/ijo.2020.03.16","article-title":"Efficacy and safety of 0.0015% tafluprost versus 0.005% latanoprost in primary open angle glaucoma, ocular hypertension:A meta-analysis","volume":"13","author":"Yang","year":"2020","journal-title":"Int J Ophthalmol"},{"issue":"(Suppl 4)","key":"R35-20251006","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1016\/S0039-6257(01)00213-2","article-title":"Mechanism of action of bimatoprost (Lumigan)","volume":"45","author":"Brubaker","year":"2001","journal-title":"Surv Ophthalmol"},{"key":"R36-20251006","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ajo.2009.12.003","article-title":"Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension","volume":"149","author":"Katz","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R37-20251006","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/bjo.87.1.57","article-title":"A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension","volume":"87","author":"Whitcup","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R38-20251006","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/bjo.2007.135111","article-title":"Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma:A meta-analysis of randomised clinical trials","volume":"93","author":"Honrubia","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R39-20251006","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1177\/112067210501500304","article-title":"Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%\/dorzolamide 2% fixed combination","volume":"15","author":"Day","year":"2005","journal-title":"Eur J Ophthalmol"},{"key":"R40-20251006","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/bjophthalmol-2012-303040","article-title":"Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension:A 12-week, randomised, double-masked trial","volume":"97","author":"Day","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R41-20251006","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","article-title":"Intraocular pressure-lowering effects of all commonly used glaucoma drugs:A meta-analysis of randomized clinical trials","volume":"112","author":"van der Valk","year":"2005","journal-title":"Ophthalmology"},{"key":"R42-20251006","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0002-9394(03)00098-9","article-title":"A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure:A 12-week, randomized, masked-evaluator multicenter study","volume":"135","author":"Parrish","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R43-20251006","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0002-9394(02)01827-5","article-title":"A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma","volume":"135","author":"Noecker","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R44-20251006","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/IJG.0b013e3181c4aeac","article-title":"Prostaglandin efficacy and safety study undertaken by race (the PRESSURE study)","volume":"19","author":"Birt","year":"2010","journal-title":"J Glaucoma"},{"key":"R45-20251006","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3906\/sag-1405-23","article-title":"Periocular changes in topical bimatoprost and latanoprost use","volume":"45","author":"Karslio\u011flu","year":"2015","journal-title":"Turk J Med Sci"},{"key":"R46-20251006","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s10384-011-0075-6","article-title":"Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost","volume":"55","author":"Aihara","year":"2011","journal-title":"Jpn J Ophthalmol"},{"key":"R47-20251006","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s10384-004-0110-y","article-title":"Latanoprost and pigmentation","volume":"48","author":"Grierson","year":"2004","journal-title":"Jpn J Ophthalmol"},{"key":"R48-20251006","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/IOP.0b013e31817d81df","article-title":"Periorbital changes associated with topical bimatoprost","volume":"24","author":"Filippopoulos","year":"2008","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"R49-20251006","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ogla.2019.10.002","article-title":"Evaluation of generic versus original prostaglandin analogues in the treatment of glaucoma:A systematic review and meta-analysis","volume":"3","author":"Steensberg","year":"2020","journal-title":"Ophthalmol Glaucoma"},{"key":"R50-20251006","first-page":"471","article-title":"Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden","volume":"3","author":"Bergstr\u00f6m","year":"2009","journal-title":"Clin Ophthalmol"},{"key":"R51-20251006","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1089\/jop.2012.0186","article-title":"Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma:A systematic review and meta-analysis","volume":"29","author":"Quaranta","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"R52-20251006","first-page":"567","article-title":"Latanoprost twice daily is less effective than once daily:Indication of receptor subsensitivity?Curr Eye Res","volume":"17","author":"Lind\u00e9n","year":"1998"},{"key":"R53-20251006","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s12325-020-01277-2","article-title":"Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma:Pooled efficacy\/safety analysis of phase 3 MERCURY-1 and -2","volume":"37","author":"Asrani","year":"2020","journal-title":"Adv Ther"},{"key":"R54-20251006","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1136\/bjophthalmol-2014-305908","article-title":"A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma:The VOYAGER study","volume":"99","author":"Weinreb","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R55-20251006","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ophtha.2016.01.019","article-title":"Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension:The APOLLO study","volume":"123","author":"Weinreb","year":"2016","journal-title":"Ophthalmology"},{"key":"R56-20251006","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/IJG.0000000000002030","article-title":"A Randomized, controlled comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension:The dolomites study","volume":"31","author":"Walters","year":"2022","journal-title":"J Glaucoma"},{"key":"R57-20251006","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s40265-018-1016-1","article-title":"Omidenepag isopropyl ophthalmic solution 0.002%:First global approval","volume":"78","author":"Duggan","year":"2018","journal-title":"Drugs"},{"key":"R58-20251006","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/IJG.0000000000001221","article-title":"Phase 2, randomized, dose-finding studies of omidenepag isopropyl, a selective EP2 agonist, in patients with primary open-angle glaucoma or ocular hypertension","volume":"28","author":"Aihara","year":"2019","journal-title":"J Glaucoma"},{"key":"R59-20251006","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajo.2020.06.003","article-title":"Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension:The phase 3 AYAME study","volume":"220","author":"Aihara","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"R60-20251006","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3109\/02713683.2011.593725","article-title":"A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension","volume":"36","author":"Schachar","year":"2011","journal-title":"Curr Eye Res"},{"key":"R62-20251006","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/bjophthalmol-2016-309023","article-title":"Ocular hypotensive effect of the novel EP3\/FP agonist ONO-9054 versus Xalatan:Results of a 28-day, double-masked, randomised study","volume":"101","author":"Miller Ellis","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"R63-20251006","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1350-9462(01)00005-2","article-title":"Blood flow in the optic nerve head and factors that may influence it","volume":"20","author":"Hayreh","year":"2001","journal-title":"Prog Retin Eye Res"},{"key":"R64-20251006","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/bjo.2008.138024","article-title":"Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma","volume":"92","author":"Quaranta","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R65-20251006","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/OPTH.S6480","article-title":"Bimatoprost in the treatment of eyelash hypotrichosis","volume":"4","author":"Law","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"R66-20251006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40123-012-0005-9","article-title":"Topical isopropyl unoprostone for retinitis pigmentosa:Microperimetric results of the phase 2 clinical study","volume":"1","author":"Yamamoto","year":"2012","journal-title":"Ophthalmol Ther"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2706_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:58:16Z","timestamp":1786647496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2706_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2706_22","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"2022-10-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}